Format

Send to

Choose Destination
Endocr Rev. 2008 May;29(3):367-79. doi: 10.1210/er.2007-0031. Epub 2008 Feb 21.

Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Author information

1
Department of Medicine, Division of Endocrinology, ML 0547, University of Cincinnati, Vontz Center for Molecular Studies, 3125 Eden Avenue, Cincinnati, Ohio 45267-0547, USA.

Abstract

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic beta-cells or a reduction in beta-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

PMID:
18292465
PMCID:
PMC2528856
DOI:
10.1210/er.2007-0031
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center